Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 101–200 of 1,000
Molecular networks for the study of TCM Pharmacology
Zhao, J., Jiang, P., & Zhang, W. (2010) · Briefings in Bioinformatics · doi:10.1093/bib/bbp063 · Cited by 204
Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data
Zhao, X.-M., Iskar, M., Zeller, G., Kuhn, M., van Noort, V., & Bork, P. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002323 · Cited by 201
“In total, 117 drug pairs approved as effective combinations until November 2010 have specific targets, when metabolizing enzymes and unspecific protein binders are excluded [16].”
BackgroundSelf-citationBipartite graphs in systems biology and medicine: a survey of methods and applications
Pavlopoulos, G. A., Kontou, P. I., Pavlopoulou, A., Bouyioukos, C., Markou, E., & Bagos, P. G. (2018) · GigaScience · doi:10.1093/gigascience/giy014 · Cited by 191
“Nine of those were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs [116].”
Tatonetti, N. P., Fernald, G. H., & Altman, R. B. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000214 · Cited by 203
Xie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
Application of text mining in the biomedical domain
Fleuren, W. W. M., & Alkema, W. (2015) · Methods · doi:10.1016/j.ymeth.2015.01.015 · Cited by 193
Targeting breast cancer stem cells
McDermott, S. P., & Wicha, M. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.005 · Cited by 193
“Computational approachesprovideamechanism topredict molecular targets and potential side-effects (Campillos et al., 2008; Keiser et al., 2009).”
BackgroundDrug-induced adverse events prediction with the LINCS L1000 data
Wang, Z., Clark, N. R., & Ma’ayan, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw168 · Cited by 195
Computational prediction of drug-drug interactions based on drugs functional similarities
Ferdousi, R., Safdari, R., & Omidi, Y. (2017) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2017.04.021 · Cited by 192
Zong, N., Kim, H., Ngo, V., & Harismendy, O. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx160 · Cited by 188
Docking techniques in pharmacology: How much promising?
Gupta, M., Sharma, R., & Kumar, A. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.06.005 · Cited by 186
Graph neural network approaches for drug-target interactions
Zhang, Z., Chen, L., Zhong, F., Wang, D., Jiang, J., Zhang, S., Jiang, H., Zheng, M., & Li, X. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.102327 · Cited by 180
In silico drug repositioning – what we need to know
Liu, Z., Fang, H., Reagan, K., Xu, X., Mendrick, D. L., Slikker, W., & Tong, W. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.005 · Cited by 183
Docking and chemoinformatic screens for new ligands and targets
Kolb, P., Ferreira, R. S., Irwin, J. J., & Shoichet, B. K. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.08.003 · Cited by 193
Nowak-Sliwinska, P., Scapozza, L., & Ruiz i Altaba, A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.005 · Cited by 183
“Indeed, side-effects observed in clinical phases of drug trials were exploited as a potential source of phenotypic information [212].”
BackgroundTang, J., & Aittokallio, T. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 175
“chemical similarity, respectively [84].”
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
Hampel, H., (APMI), F. T. A. P. M. I., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179932 · Cited by 176
“Campillos and colleagues (2008) used drug-drug and drug-target networks enriched with side-effect phenotype information for all approved drugs across many disease indications and based on side-effect similarities predicted and experimentally validated novel drug-target relations [584].”
Semantic similarity and machine learning with ontologies
Kulmanov, M., Smaili, F. Z., Gao, X., & Hoehndorf, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa199 · Cited by 170
“Consequently, ontologies play a role in many different biomedical machine learning tasks such as genotype–phenotype association prediction [45, 46, 118], protein function prediction [49], drug–target prediction [119, 120], protein–protein interaction prediction [37, 48, 112], gene–disease association prediction [44, 1…”
BackgroundPredicting New Indications for Approved Drugs Using a Proteochemometric Method
Dakshanamurthy, S., Issa, N. T., Assefnia, S., Seshasayee, A., Peters, O. J., Madhavan, S., Uren, A., Brown, M. L., & Byers, S. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300576q · Cited by 168
Jeon, J., Nim, S., Teyra, J., Datti, A., Wrana, J. L., Sidhu, S. S., Moffat, J., & Kim, P. M. (2014) · Genome Medicine · doi:10.1186/preaccept-8096551512514564 · Cited by 166
“Recently, system biology approaches have been intensively applied to discover novel effects for existing drugs by analyzing large data sets such as gene expression profiles [13], side-effect similarity [14] and disease-drug networks [15].”
BackgroundLehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
“and by analysis of drug activities and side effect”
BackgroundA network medicine approach to human disease
Zanzoni, A., Soler-López, M., & Aloy, P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.001 · Cited by 171
“A similar analysis was recently developed by measuring the side-effect similarity of marketed drugs to identify potential new targets [83].”
MethodChanging Trends in Computational Drug Repositioning
Yella, J. K., Yaddanapudi, S., Wang, Y., & Jegga, A. G. (2018) · Pharmaceuticals · doi:10.3390/ph11020057 · Cited by 166
Charting the molecular network of the drug target Bcr-Abl
Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Köcher, T., Mechtler, K., Bennett, K. L., & Superti-Furga, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900653106 · Cited by 170
“Furthermore, drugs often have undesired side effects by impinging on different pathways that, in turn, may be shared by different diseases (9, 10).”
BackgroundAssessing Drug Target Association Using Semantic Linked Data
Chen, B., Ding, Y., & Wild, D. J. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002574 · Cited by 166
“However other drug-target prediction methods have been the subject of recent publications [7,17,34], and we thus sought to consider how the effectiveness of SLAP compares with these methods.”
BackgroundResultSystems Pharmacology in Small Molecular Drug Discovery
Zhou, W., Wang, Y., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020246 · Cited by 162
Neuro-symbolic representation learning on biological knowledge graphs
Alshahrani, M., Khan, M. A., Maddouri, O., Kinjo, A. R., Queralt-Rosinach, N., & Hoehndorf, R. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx275 · Cited by 150
“side effects provide some information about drugs’ modes of action [Campillos et al.(2008)]. We train a logistic regression classifier to predict whether a pair of drugs (represented by the embeddings we generate) share an indication or target. To make our input data comparable to studies that compare only drugs’ side…”
BackgroundResultInfluentialToxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
Liu, S., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.003 · Cited by 159
Drug–target interaction prediction through domain-tuned network-based inference
Alaimo, S., Pulvirenti, A., Giugno, R., & Ferro, A. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt307 · Cited by 170
“In Yildirim et al. (2007), a bipartite graph linking US Food and Drug Administration-approved drugs to proteins by DT binary associations is exploited.”
BackgroundWang, Y., Chen, S., Deng, N., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078518 · Cited by 163
“Thus side-effects data is useful to infer whether two drugs share similar target proteins [25].”
Literature Mining for the Discovery of Hidden Connections between Drugs, Genes and Diseases
Frijters, R., van Vugt, M., Smeets, R., van Schaik, R., de Vlieg, J., & Alkema, W. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000943 · Cited by 161
“showed how text mining of drug labels, can be used to infer whether two drugs share the same target [80].”
An update on Drug Repurposing: Re-written saga of the drug’s fate
GNS, H. S., GR, S., Murahari, M., & Krishnamurthy, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.127 · Cited by 161
Mapping Adverse Drug Reactions in Chemical Space
Scheiber, J., Jenkins, J. L., Sukuru, S. C. K., Bender, A., Mikhailov, D., Milik, M., Azzaoui, K., Whitebread, S., Hamon, J., Urban, L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801546k · Cited by 160
Huang, J., Niu, C., Green, C. D., Yang, L., Mei, H., & Han, J. J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002998 · Cited by 175
“…algorithm with previously published methods, we selected several representative methods in the field of DDI prediction [7,13,15] and also covered some approaches that were originally designed for inferring novel potential targets of drugs but can also be used to infer drug interactions [8,9,10,11].”
BackgroundMethodInfluentialStructure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 163
“A number of computational methodologies have been developed where relate putative protein targets through their ligand chemistry [15,16] or biological profiles (e.g., binding activities [17], expression profiles [18,19], side-effects [20]).”
BackgroundMerging Systems Biology with Pharmacodynamics
Iyengar, R., Zhao, S., Chung, S.-W., Mager, D. E., & Gallo, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003563 · Cited by 156
Computational drug repositioning through heterogeneous network clustering
Wu, C., Gudivada, R. C., Aronow, B. J., & Jegga, A. G. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-s5-s6 · Cited by 152
“Based on this principle, some computational approaches (see recent review [5]) have been developed and applied to identify drug repositioning candidates ranging from mapping gene expression profiles with drug response profiles [6-12], to side-effect based similarities [13-15].”
BackgroundChang, J., Kim, Y., & Kwon, H. J. (2016) · Natural Product Reports · doi:10.1039/c5np00107b · Cited by 162
Design of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design
Pihan, E., Colliandre, L., Guichou, J.-F., & Douguet, D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts186 · Cited by 142
“The rationale is that a drug usually acts on more than one target and may exhibit previously unknown functions due to promiscuous off-target interactions explaining efficacy and/or side-effects (Campillos et al., 2008).”
Comparison Study of Computational Prediction Tools for Drug-Target Binding Affinities
Thafar, M., Raies, A. B., Albaradei, S., Essack, M., & Bajic, V. B. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00782 · Cited by 144
“For example, some studies predicted DTIs by integrating drug side-effects information (Campillos et al., 2008; Mizutani et al., 2012), or drug-diseases interaction (Wang W.”
BackgroundDrug-Induced Regulation of Target Expression
Iskar, M., Campillos, M., Kuhn, M., Jensen, L. J., van Noort, V., & Bork, P. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000925 · Cited by 142
“Chemical structural similarity is an indicator of shared drug targets and mechanism of action [14–16].”
BackgroundSelf-citationRole of systems pharmacology in understanding drug adverse events
Berger, S., & Iyengar, R. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.114 · Cited by 148
“21,22 Campillos et al. 23 also utilized the knowledge of drug chemical structures for the prediction of drug off-targets.”
BackgroundPredicting the frequencies of drug side effects
Galeano, D., Li, S., Gerstein, M., & Paccanaro, A. (2020) · Nature Communications · doi:10.1038/s41467-020-18305-y · Cited by 156
Sahoo, B. M., Ravi Kumar, B. V. V., Sruti, J., Mahapatra, M. K., Banik, B. K., & Borah, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.628144 · Cited by 137
“In addition to this, it includes information about promising drug candidates which are in various phases of pre-clinical, clinical and experimental stages of drug discovery and development process (Campillos et al., 2008; Brown and Patel, 2017).”
BackgroundTools for in silico target fishing
Cereto‐Massagué, A., Ojeda, M. J., Valls, C., Mulero, M., Pujadas, G., & García-Vallvé, S. (2014) · Methods · doi:10.1016/j.ymeth.2014.09.006 · Cited by 156
“[53] used phenotypic side-effect similarities to infer whether two drugs shared a target.”
BackgroundMethodInfluentialCompound promiscuity: what can we learn from current data?
Hu, Y., & Bajorath, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.03.002 · Cited by 160
Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.008 · Cited by 154
“775–784 35 Pang, K.S. et al. eds (2010) Enzyme- and Transporter-Based Drug–Drug Interactions: Progress and Future Challenges, Springer”
BackgroundInfluential90 years of monoamine oxidase: some progress and some confusion
Tipton, K. F. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1881-5 · Cited by 149
Drug Side-Effect Prediction Based on the Integration of Chemical and Biological Spaces
Yamanishi, Y., Pauwels, E., & Kotera, M. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci2005548 · Cited by 144
On the origins of drug polypharmacology
Jalencas, X., & Mestres, J. (2013) · MedChemComm · doi:10.1039/c2md20242e · Cited by 138
Old friends in new guise: repositioning of known drugs with structural bioinformatics
Haupt, V. J., & Schroeder, M. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr011 · Cited by 153
Öztürk, H., Özkırımlı, E., & Özgür, A. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0977-x · Cited by 160
“Recent studies have adopted chemogenomics approaches for predicting drug-target interactions [5–17] based on genomic similarity of proteins and/or chemical similarity of ligands using different computational models and classification algorithms.”
BackgroundPubChem as a Source of Polypharmacology
Chen, B., Wild, D., & Guha, R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9001876 · Cited by 140
DRUG TARGET PREDICTIONS BASED ON HETEROGENEOUS GRAPH INFERENCE
Wang, W., Yang, S., & Li, J. (2012) · Biocomputing 2013 · doi:10.1142/9789814447973_0006 · Cited by 141
“Recycling” Classical Drugs for Malaria
Teixeira, C. A. S., Vale, N., Pérez, B. C., Gomes, A., Gomes, J. R. B., & Gomes, P. A. C. (2014) · Chemical Reviews · doi:10.1021/cr500123g · Cited by 154
Comprehensive prediction of drug-protein interactions and side effects for the human proteome
Zhou, H., Gao, M., & Skolnick, J. (2015) · Scientific Reports · doi:10.1038/srep11090 · Cited by 138
Detection of Drug-Drug Interactions by Modeling Interaction Profile Fingerprints
Vilar, S., Uriarte, E., Santana, L., Tatonetti, N. P., & Friedman, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058321 · Cited by 149
Network-based machine learning and graph theory algorithms for precision oncology
Zhang, W., Chien, J., Yong, J., & Kuang, R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0029-7 · Cited by 124
“The paper 64 derived drug – drug similarities based on mining the side-effect description from medical symptoms in the Uni fi ed Medical Language System ontology.”
BackgroundPredicting adverse side effects of drugs
Huang, L.-C., Wu, X., & Chen, J. Y. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-s5-s11 · Cited by 133
“chemical compounds, protein targets, and side effects observed at the physiological level [4].”
BackgroundMethodPredicting Adverse Drug Events Using Pharmacological Network Models
Cami, A., Arnold, A., Manzi, S., & Reis, B. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002774 · Cited by 131
“Jackard coefficient – based predictors have been used in several earlier studies ( 22 , 23 ); specifically, jackard-drug-max wasearlierusedin( 19 ).”
BackgroundMethodModulatory profiling identifies mechanisms of small molecule-induced cell death
Wolpaw, A. J., Shimada, K., Skouta, R., Welsch, M. E., Akavia, U. D., Pe'er, D., Shaik, F., Bulinski, J. C., & Stockwell, B. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106149108 · Cited by 133
“Small molecules, even approved drugs, can have pleiotropic effects on cells (54, 55).”
BackgroundSystems Pharmacology to Predict Drug Toxicity: Integration Across Levels of Biological Organization
Bai, J. P. F., & Abernethy, D. R. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140248 · Cited by 143
Drug target prediction using adverse event report systems: a pharmacogenomic approach
Takarabe, M., Kotera, M., Nishimura, Y., Goto, S., & Yamanishi, Y. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts413 · Cited by 128
“Another promising approach is to use pharmacological use of side effect similarity has been recently proposed to whether two drugs share a target (Campillos et al. , 2008). method requires drug package inserts that describe the detailed limitation, several methods have been proposed to predict…”
BackgroundUsing artificial intelligence methods to speed up drug discovery
Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1621284 · Cited by 124
“This includes the case of sharing similar side-effects [50 – 52].”
BackgroundLigand–receptor interaction platforms and their applications for drug discovery
Fang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.715631 · Cited by 124
“Furthermore, ligand binding should also perform at the proteome level, given that polypharmacology may play synergistic or detrimental effects of drug molecules [175,176].”
BackgroundAn Algorithmic Framework for Predicting Side Effects of Drugs
Atias, N., & Sharan, R. (2011) · Journal of Computational Biology · doi:10.1089/cmb.2010.0255 · Cited by 128
“Applications of such approaches range from predicting gene-disease associations and drug-target relations (Campillos et al., 2008) to discovering new drugs (Lamb et al., 2006).”
InfluentialA Computational Approach to Finding Novel Targets for Existing Drugs
Li, Y. Y., An, J., & Jones, S. J. M. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002139 · Cited by 141
“similarity [10].”
Behavioral screening for neuroactive drugs in zebrafish
Rihel, J., & Schier, A. F. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20910 · Cited by 143
A Comprehensive Review of Computational Methods For Drug-Drug Interaction Detection
Qiu, Y., Zhang, Y., Deng, Y., Liu, S., & Zhang, W. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3081268 · Cited by 148
Recent advances and method development for drug target identification
Chan, J. N. Y., Nislow, C., & Emili, A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.002 · Cited by 143
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126
Parisi, D., Adasme, M. F., Sveshnikova, A. N., Bolz, S. N., Moreau, Y., & Schroeder, M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.004 · Cited by 135
“These approaches include comprehensive and computational comparisons of disease phenotypes and drug side effects [28,29] as well as comparisons of gene expression profiles [30].”
BackgroundHarnessing network pharmacology in drug discovery: an integrated approach
Joshi, C. P., Baldi, A., Kumar, N., & Pradhan, J. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03625-3 · Cited by 138
“The drug of interest and target network can provide information about similar drugs having affinities for similar targets, by analysing the connections between sets of drugs and targets (Campillos et al. 2008).”
Kell, D. B. (2013) · The FEBS Journal · doi:10.1111/febs.12268 · Cited by 121
Gene Ontology and KEGG Pathway Enrichment Analysis of a Drug Target-Based Classification System
Chen, L., Chu, C., Lu, J., Kong, X., Huang, T., & Cai, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126492 · Cited by 138
“Other computational methods predict DTIs by similarities in phenotypic side effects [5] or chemical structures [6] or by connections between chemicals with chemicals/proteins [6].”
MethodRayhan, F., Ahmed, S., Shatabda, S., Farid, D. M., Mousavian, Z., Dehzangi, A., & Rahman, M. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18025-2 · Cited by 120
“Prediction of new drug target interactions can lead the researchers to find new uses for old drugs and to realize the therapeutic profiles or side effects thereof [2, 3, 4].”
BackgroundCao, D., Liu, S., Xu, Q., Lü, H., Huang, J.-H., Hu, Q., & Liang, Y. (2012) · Analytica Chimica Acta · doi:10.1016/j.aca.2012.09.021 · Cited by 132
Drug Target Protein-Protein Interaction Networks: A Systematic Perspective
Feng, Y., Wang, Q., & Wang, T. (2017) · BioMed Research International · doi:10.1155/2017/1289259 · Cited by 118
“[8] used phenotypic sideeffect similarities to infer whether two drugs share a target.”
MethodIskar, M., Zeller, G., Blattmann, P., Campillos, M., Kuhn, M., Kaminska, K. H., Runz, H., Gavin, A., Pepperkok, R., van Noort, V., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.20 · Cited by 118
“Towards drug repositioning from drug-induced modules Drug repositioning, that is the application of existing drugs to new indications, on the basis of computational prediction, has gained increasing attention (Campillos et al, 2008; Keiser et al, 2009; Iorio et al, 2010; Gottlieb et al, 2011).”
BackgroundSelf-citationSystematic identification of proteins that elicit drug side effects
Kuhn, M., Al Banchaabouchi, M., Campillos, M., Jensen, L. J., Gross, C., Gavin, A., & Bork, P. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.10 · Cited by 120
Self-citationFox, R. J., Thompson, A., Baker, D., Baneke, P., Brown, D., Browne, P., Chandraratna, D., Ciccarelli, O., Coetzee, T., Comi, G., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512458169 · Cited by 117
DINIES: drug–target interaction network inference engine based on supervised analysis
Yamanishi, Y., Kotera, M., Moriya, Y., Sawada, R., Kanehisa, M. I., & Goto, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku337 · Cited by 126
Systems biology and its application to the understanding of neurological diseases
Villoslada, P., Steinman, L., & Baranzini, S. E. (2009) · Annals of Neurology · doi:10.1002/ana.21634 · Cited by 123
“50 A recent study analyzing the protein network involved in inherited ataxias exemplifies the power of this approach.”
BackgroundOprea, T. I., Nielsen, S. K., Ursu, O., Yang, J. J., Taboureau, O., Mathias, S. L., Kouskoumvekaki, I., Sklar, L. A., & Bologa, C. G. (2011) · Molecular Informatics · doi:10.1002/minf.201100023 · Cited by 114
Alam, S., & Khan, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-23768-7 · Cited by 113
Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action
Hillenmeyer, M. E., Ericson, E., Davis, R. W., Nislow, C., Koller, D., & Giaever, G. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r30 · Cited by 112
“For example, one such approach [17] looks for similarities in gene expression profiles in response to the drug; whereas another [18] looks for similarities in side effects.”
BackgroundDrug–target interaction predication via multi-channel graph neural networks
Li, Y., Qiao, G., Wang, K., & Wang, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab346 · Cited by 112
Biomedical Text Mining and Its Applications
Rodriguez‐Esteban, R. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000597 · Cited by 112
“looking at examples such as [64–67].”
Xu, R., & Wang, Q. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-181 · Cited by 107
“These approaches include repositioning based on chemical similarity [4,5], molecular activity similarity [6,7], molecular docking [8], gene expression similarity [9,10], and drug side effect similarity [11].”
Iskar, M., Zeller, G., Zhao, X., van Noort, V., & Bork, P. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.11.010 · Cited by 124
Self-citationCao, D., Liang, Y., Yan, J., Tan, G., Xu, Q., & Liu, S. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400127q · Cited by 119
Network medicine framework for identifying drug-repurposing opportunities for COVID-19
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025581118 · Cited by 107
Yang, L., Wang, K., Chen, J., Jegga, A. G., Luo, H., Shi, L., Wan, C., Guo, X., Qin, S., He, G., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002016 · Cited by 103
“Identification of off-targets has potential application in drug repurposing [44,45] and personalized medicine [13,46].”
BackgroundApplication of network link prediction in drug discovery
Abbas, K., Abbasi, A., Dong, S., Ling, N., Yu, L., Chen, B., Cai, S., & Hasan, Q. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04082-y · Cited by 122
“Drug–drug side effect prediction is an important task in its own right, but some researchers like Campillos et al. [22] use drug side effects as features for predicting novel target prediction.”
BackgroundMethodIdentifying Network of Drug Mode of Action by Gene Expression Profiling
Iorio, F., Tagliaferri, R., & Bernardo, D. D. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.10tt · Cited by 101
“Recently, text-mining has been proposed as an approach to estimate drug MOA similarities using similarity in drug clinical side-effects (Campillos et al., 2008; Yeh et al., 2006).”
The impact of in silico screening in the discovery of novel and safer drug candidates
Rognan, D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.034 · Cited by 119
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Zhang, W., Bai, Y., Wang, Y., & Xiao, W. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160224142812 · Cited by 112
“Also, Campillos used phenotypic side-effect similarities to infer whether two drugs share a target, identifying 13 implied drug-target relations out of 20 predictions by in vitro binding assays [27].”
BackgroundMethodThe Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
Kinnings, S., Xie, L., Fung, K. H., Jackson, R. M., Xie, L., & Bourne, P. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000976 · Cited by 109
“In recent years, several computational methodologies have been developed to predict drug-target networks based on ligand chemistry [4–6], phenotypic changes resulting from drug perturbation [7–9], or a combination of chemical features of drugs and sequence features of protein targets [10–12].”
Background
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.